A Risk Modeling Framework for the Pharmaceutical Industry by Adis, Warren
Communications of the IIMA
Volume 7 | Issue 1 Article 1
2007
A Risk Modeling Framework for the
Pharmaceutical Industry
Warren Adis
Hagan School of Business, Iona College
Follow this and additional works at: http://scholarworks.lib.csusb.edu/ciima
This Article is brought to you for free and open access by CSUSB ScholarWorks. It has been accepted for inclusion in Communications of the IIMA by
an authorized administrator of CSUSB ScholarWorks. For more information, please contact scholarworks@csusb.edu.
Recommended Citation
Adis, Warren (2007) "A Risk Modeling Framework for the Pharmaceutical Industry," Communications of the IIMA: Vol. 7: Iss. 1, Article
1.
Available at: http://scholarworks.lib.csusb.edu/ciima/vol7/iss1/1
A Risk Modeling Framework for the Pharmaceutical Industry Adis 
 
Communications of the IIMA 1 2007  Volume 7 Issue 1 
A Risk Modeling Framework for the Pharmaceutical Industry 
 
Warren Adis 





This conceptual paper seeks to advance a theoretical discussion on risk modeling and how it is used 
within the context of business process modeling.  It discusses developments in risk modeling and then 
shows how they have been applied to the USA pharmaceutical industry. The pharmaceutical industry is a 
particularly interesting example in that it is bound on one side by stringent USA government mandates, 
and on the other by a risk adverse consumer population.  A third aspect, the expanding cost structure of 
drug production and compliance, adds to the complexity of the problem.  The discussion of risk in this 
paper applies mainly to regulated industries, and may be less applicable to more unregulated industry 
sectors.   The important lesson for researchers is that a risk framework can play a significant part in 
business process modeling.  The format for this paradigm may very well resemble a process repository, 
similar to those found in knowledge management systems.  
  
INDUSTRIAL STRENGTH SYSTEMS 
 
One of the principal tasks of business process modeling (BPM) is to develop what Booch broadly calls “industrial 
strength” systems (Booch, 1994).  In complex environments one of the fundamental features of an industrial strength 
system is that it can manage the forces of internal complexity and external variability throughout the life cycle of the 
system. To build industrial strength systems researchers and practitioners often turn to the ‘best practices’ of 
industry leaders.  These best practices are accepted standards which have usually been developed over time and have 
proven themselves through benchmarking and quality assurance tests.  Yet risk analysis has often been an 
unexamined premise that is fundamental to the development of best practices.  
 
When a technical system fails, a reasonable conclusion is that the system was not stable enough to survive the 
internal and external forces that caused the system to degrade (Scott, 2000).  The failure may be ascribed to an 
incomplete or faulty process modeling technique, weak implementation, or similar problems. Though when a system 
fails and a disaster occurs or is narrowly avoided, the business and technical community also belatedly conclude that 
not enough attention was paid to possibilities outside the predicted range of events. In these instances the industry 
best practices and other benchmarks are found to be lacking.  Based on this failure scenario, the business process 
model can be modified and a different set of best practices can evolve.  The designer’s basic objective would be to 
further minimize and constrain unnecessary risk.  
 
This paper’s focus will be to highlight steps taken by the pharmaceutical industry to incorporate risk modeling in 
their system development.  It is important to note that while the U.S. pharmaceutical industry’s experience is well 
documented, these findings may not apply to other similar industrial sectors that are not so rigorously regulated.  
The pharmaceutical industry in some senses may be considered unique in that it has a fiducial responsibility in 
management and production functions.   
 
USA PHARMACEUTICAL INDUSTRY 
 
The USA pharmaceutical industry is an excellent example of a business sector that is incorporating risk planning 
into their BPM.  It is particularly useful to study this industry because it faces the complex tasks of developing, 
testing and manufacturing of drugs, has a rigorous oversight agency in the U.S. Food and Drug Administration 
(FDA), and serves a marketplace with an exceptionally low tolerance for variability in pharmaceutical products 
(FDA, 2003a; FDA, 2004).  
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Yet it is common knowledge that the pharmaceutical industry, like many mature industries, is built around 
traditional manufacturing processes and legacy information systems.  Each is based on rigid work flow patterns that 
have been optimized for efficiency and cost reductions, rather than for data integration and compliance. 
 
Attaining regulatory compliance within this environment is significant in that the following challenges have to be 
addressed: 
 
• Isolated work silos exist that have critical information trapped within the manufacturing processes.   
• Data redundancies with multiple overlapping reports sometimes confuse and obfuscate further 
analysis. 
• Data communications between processes are missing, and therefore there is no centralized control.   
• Process controls are often localized and do not provide corporate-wide problem remediation.  
• Fiscal and operational optimization has a higher priority than the need for compliance. 
• Attempts at introducing Enterprise Resource Planning (ERP) systems are often a lengthy, time 
consuming, and expensive undertaking, and results may only partially address the problem of 
compliance. 
In order to meet these issues, the FDA has adopted a new risk-based paradigm for addressing its role as an oversight 
agency for the pharmaceutical industry.  FDA guidelines state that the agency must inspect domestic drug 
manufacturing establishments at least once every 2 years.  But internal reviews show that the agency no longer has 
the resources to meet this statutory requirement.  Simply put, the FDA workload of examining registered human 
drug establishments keeps increasing, while the number of FDA human drug inspections remains static, causing an 
increasing backlog.  Therefore beginning in fiscal year 2005, as part of the Agency's mandate, the FDA is piloting a 
new initiative, the Pharmaceutical Current Good Manufacturing Practices (CGMPs) for the 21st Century (FDA, 
2004).  
 
The noteworthy points from the 2004 FDA mandates are their focus on working through these challenges, using a 
risk resolving methodology as the metric for prioritizing reporting and compliance tasks.  “The model is based on a 
risk-ranking and filtering method that is well-recognized, objective, and rigorously systematic. This approach should 
help the Agency make the best use of its limited surveillance and enforcement resources while maximizing the 
impact of those resources on the public health” (FDA, 2004).  In essence, the functionality for this model may very 
well resemble a process management repository, where definitions, procedures, and reports are stored and control 




Clearly, regulatory oversight is a critical component for ensuring pharmaceutical quality and efficacy. During the 
development and production life cycle of human drugs, vaccines, and other biological products, the FDA acts as the 
supervisory agency, assuring that industry best practices are followed (GAMP, 2001).  Furthermore, the FDA wants 
oversight to guarantee that industry approved steps are followed for identifying and isolating problems with such 
issues as contaminants and failed processes. Additional areas of compliance ensure that approved Corrective And 
Preventive Actions (CAPA) are taken. 
 
In other words, the FDA is using the concept of risk prevention to focus and drive these initiatives. This leads 
directly to developing and building verifiable processes that identify, control, and reduce risks in the product or 
services.  In brief, the FDA has mandated that the pharmaceutical industry follows the risk methodology outlined 
below. Each step is verifiable, in that critical data can be captured and reported in a timely fashion to the agency 
(FDA, 2004). 
 
• The first action of an operational risk based system is to identify a hazard, nonconformity, or source of 
variability. 
• The next step is to prioritize the seriousness of the risk using FDA and industry standards.  
• The system then triggers an alert which serves as a marker for remediation.  
• In parallel, the integrated system triggers a system-wide alert and begins the risk log. 
• The system then searches for the hazard, as well as the root cause(s) of the problem.  
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• The corrective mechanisms within the system isolate the threat from the process, and address the root 
cause(s). 
• The methodology is iterative, continually searching for and removing remaining residual risks.  
These steps provide verifiable oversight and control, without unnecessary complexity.  As a minimum the system 
continuously monitors key processes, highlighting critical measurement of variability.  The FDA then uses the risk 
methodology to filter and prioritize this data and thereby determine the frequency and severity of a risk for different 
production practices and design changes.  
 
This is accomplished by applying risk management statistics to the oversight and control systems data.   The 
analyzed results in combination with the industries best business practices provide an ongoing evaluation of the 
severity of each risk against the likelihood of its occurrence. The FDA can then compare this information with its 




An essential role for business management is to build systems that enhance competitive advantage.  While there are 
different approaches to achieving this, it is fair to say that management seeks on the one had efficiency and 
effectiveness in its business processes, while on the other hand it looks to minimize and control risk.   One of the 
most important features in total risk management is that it evaluates the changing context within the business 
process model.  The FDA and the pharmaceutical industry have an overlapping functionality.  Each knows that 
efficient and effective processes create a strong environment conducive to best business practices.  Yet the FDA 
does not wish to micro-manage the pharmaceutical industry but rather to monitor and evaluate those identifiable 
processes that are the foci for risk. 
 
At each phase of the system life cycle, the FDA and the pharmaceutical industry are on the same page, reviewing the 
context, identifying and prioritizing the threat level of potential hazardous forces within the environment.  It is a 
shared analysis, looking at the same data, though not necessarily in the same time frame.  A pharmaceutical 
company would be monitoring and reviewing critical data in real time, and less critical data in a longer timeframe.   
The FDA function is more procedural, in that it wants to assure that the pharmaceutical companies have the 
mechanisms in place to accomplish their tasks in the established timeframe. 
 
Therefore the FDA maintains its oversight of the procedures and evaluative processes, while the pharmaceutical 
companies are focusing on building and managing iterative systems that search for those factors which may raise the 
risk level within the system. These factors include the direct causes of the particular threat, as well as the indirect 
and secondary causes. Following the identification of the hazard, there is a determination of its probability of 
occurrence as well as the potential damage. This is standard decision making theory where risk is the probability of 
occurrence of loss multiplied by its respective magnitude.  Risk management then uses FDA approved best business 
practices to establish procedures for preventive or corrective actions.  This approach is particularly valuable in an 
environment where multiple, seemingly negligible risks have the combined potential to cause harm.  
 
These factors can be summarized in the following formulas.  The first deals with risk estimation, the mapping of the 
probability of the event against the severity of harm.   The basic formulation for risk estimation is the probability (P) 
of the identified event evaluated by its consequence (C):  
R = {P, C} 
Once the initial risk level has been evaluated, then decisions can be made on the FDA acceptance level associated 
with the hazard.  This risk acceptance level would take into consideration any corrective and preventative actions 
(CAPA) which would act as mitigating forces.  CAPA would act to reduce the probability of occurrence as well as 
to limit and control the overall damage.  Therefore in the next formula corrective and preventative actions (CAPA) 
are introduced to the function.    
R = {P, C, CAPA} 
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This formula is then fine-tuned by actual design and production experiences as well as industry best practice 
standards.  A risk matrix is a useful tool for conceptualizing this approach (Figure 1). The vertical axis shows the 
probability of an event occurring, while the horizontal axis shows levels of severity. The vertical axis displays a 
range of probabilities from rare to frequent, while the horizontal axis has multiple outcomes from negligible to 
catastrophic.  In this matrix, each hazard entity is located within a specific X,Y region, ranging from standard 
acceptable risk level, “As Low as Reasonably Practical” (ALARP), to strategic damage.  The traditional matrix has 
been expanded to show the effect of CAPA procedures and protocols which can drive down and contain the 
potential hazards. This mitigating effect is indicated by the dotted line pushing back the probability and magnitude 
of the threat. Lastly surrounding each of the entities is a dotted black border to indicate a series of alarms, stored 
procedures and methods aimed at containing a particular hazard from escalating into a significant threat. 
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Risk Modeling in Pharmaceutical Manufacturing 
 
The stated goals of the pharmaceutical industry are to manufacture products with the highest quality, safety and 
efficacy, at the lowest responsible cost.  In order to achieve these goals the industry has to focus on process design in 
manufacturing, supply chain management, and overall system security.  Over time, hazards and variability have 
been reduced, and manufactured products have achieved a very safe tolerance level. Much of this has been 
accomplished using traditional design methodologies that focus on building systems that meet fixed specifications. 
These improvements come from best practices and regulatory guidelines that address problems with quality, 
variability in processes, time induced degradations, and the like.  
 
   STRATEGIC  DAMAGE 
 
LIKELY     
  ALARP   
 
RARE    REGION  
    
 
UNREALISTIC  STANDARD  RISK  LEVEL  
 
NEGLIGIBLE  MINOR  CRITICAL  DISASTER 
CAPA 
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So in theory “good designs do not fail”, because in part the system specifications are often based on some risk 
analysis.  Manufacturing systems take into consideration the mean time between failure of components, and 
frequently sample production runs for quality.  These are unstated acknowledgements of production risks (de 
Neufville, 2004). 
 
Even without the existence of this new FDA risk mandate, corporations in the pharmaceutical industry would have 
eventually realized the advantages of this methodology in providing quality performance, as well as intelligent 
management of compliance.  Both must be accomplished cost effectively with minimal expenditure of resources.  
Risk methodology provides additional tools to accomplish these objectives.   
In fact BPM and best practices are strengthened by the formal acknowledgement of risk, and procedures for CAPA 
mitigation.  These can act as an overall catalyst for the elimination of system stoppages and failures on one hand, 
and on the other be the basis for cost effective management and production.  In this way managers can guarantee 
system and product integrity, and provide compliance in real time reports. This is the needed assurance that 
companies are meeting both their internal objectives as well as the necessary regulatory inspection standards for 
pharmaceutical products. 
 
Yet the question remains as to how BPM design methodology can best incorporate risk management.  In complex 
organizations such as those found in the pharmaceutical industry, there is also the practical question of how to 
transmit, integrate and manage best practices and compliance reporting.  This is taken up in the next sector which 
discusses the concept of a BPM/process repository.  This may very well serve as part of the  organizational 
“intelligence”, assuring that the best practices are actively taken up.  
 
PROCESS MANAGEMENT REPOSITORY 
 
So far the discussion has focused on the concept of risk management through best practices.  Yet the strength of risk 
management is its potential for straight forward implementation within the corporate structure.  One of the newer 
BPM approaches is the development of a process management repository that employs risk management functions. 
 
A process management repository would contain data and methods which underpin best practices, risk management 
and compliance with the FDA.  The Enterprise Risk Management (ERM) framework described by the Committee of 
Sponsoring Organizations of the Treadway Commission (COSO) and those of IT Governance Institute’s (ITGI) 
COBIT 4.0 methodology partially outline this approach.  With the ERM framework, corporations are building a 
broad enterprise-wide system of internal controls and management practices. The ITGI’s framework is also broad 
but more focused on developing a roadmap for IT best practices. In fact part of the ITGI best practices comes from 
the Enterprise Risk Management (ERM) framework.  The overall result is that both the ERM and COBIT 
frameworks address building an overall philosophy, as well as infrastructure to manage both risk and performance.  
  
These functional aspects of ERM and COBIT can be implemented using knowledge management systems, and in 
particular its process management repository (PMR). This implementation would use such tools as data dictionaries 
describing risk classes, repositories for storing critical compliance information, best practices, CAPA 
methods/procedures, and performance measurements (Tiwana, 2000).  Using the same logic, a PMR could very well 
be the basis for a future FDA infrastructure focusing on the immediate need for oversight and the reduction of risk.  
This infrastructure would actively manage best practice and verifiable compliance. Therefore a critical element in 
moving to the FDA model, or to any risk centered model, is the successful conceptualizing and implementation of a 
process repository (Alavi, 2001).  
 
Some of the characteristics of the repository for the pharmaceutical industry could be:  
• FDA regulations  
• Corporate policies and procedures  
• Corporate environment for risk management with supporting surveys  
• Industry best practice mandates with supporting evidence 
• Test plans with test outcomes 
• Business process flows, theoretical and actual  
• Risk libraries with stored CAPA plans and self activated procedures 
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• Control libraries documenting control history  
• Evidence for compliance in a transparent electronic format 
This is spelled out in greater detail in Table 1. The process repository outlined in this table becomes part of the 
overall knowledge management system that meets the compliance mandate of the FDA.  Its functionality permits on 
one hand the codifying and storing of best practices and critical data.  On the other hand it provides active 
management of risk accounting and fault management (Scott, 2002).  It is direct and focused for FDA oversight, and 
provides the foundation for further steps as the FDA matures and adopts specifications similar to ERM and COBIT. 
 
Table 1:  Process Repository. 
 
Repository  Management Risk Component 
Regulatory database  Data repository of regulatory standards and critical 
measurements 
Best Practice database Industry standard procedures 
Compensatory Services CAPA programs and procedures with triggers  
Accounting Management  
Mapping of processes Detailed description of processes and risks  
Logistic tracking  Tracking of resources, products, processes 
Data comparison Analysis of critical measurements and variability  
Change tracking Monitoring change in the process 
Design optimization Planning for performance upgrades  
Audit Audit trail showing data creation, modification, deletion 
Plug and play configuration Incorporating new systems 
Fault Management  
Alarm notification Alerting staff and control hardware of faults 
Alarm correction  Switching, and isolating supplies, processes and 
products  
Disaster recovery Isolating and recovering from disasters; logging 
activities, switching over to redundant systems  
Remote process 
reconfiguration 
Modifying process using CAPA   
Performance Management  
Capacity planning Tracking production growth 
Event scheduling Balancing production loads of scheduled processes 
Process analysis Analyzing for errors and faults, using best practices 
Test monitoring Testing samples for quality and performance 
Trouble ticketing Resolving known problems and replacing defects 
Information Management  
Data backup Securing data and configuration information 
Monitoring and testing control 
mechanisms 
Checking system controls with test data  
Creating transparency for 
internal usage and for 
Regulatory Agency 
Shared protocols for transferring information internally 
and externally 
Developing dashboards to 
quantify risks  
Straightforward visual metering of risk and performance 
levels  
Firewall filtering services Screening the information repository and monitoring 
against foreign activity  
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Pharmaceutical companies are complex organizations that best respond to pragmatic, simple approaches to risk 
management—ideally through a single integrated system that controls all risks.  Best practices and compliance 
mandates dictate that these organizations leverage their multiple systems through integration and centralized process 
management.  
 
Information technology plays a critical role in linking and controlling disparate systems in a transparent fashion. 
Furthermore, IT analytics can handle the necessary risk analysis, mediation and compliance to meet the industry 
mandate.  
 
There are many lessons that can be learned from the pharmaceutical industry and the FDA’s adoption of a risk 
methodology. The first is that risk analysis is going to play an ever greater role in meeting compliance standards of 
regulatory agencies.  The logical outcome is that risk methodologies will assume a more active part in process 
modeling.   
 
At the center of these systems will be process repositories, which may very well have a similar look, feel and 
functionality to the process repository chart outlined earlier.  Much more work needs to be done to conceptualize the 
detailed functionalities of different process repositories and to evaluate which approach best fits within the 
organizational structure of the industry.  This includes the organizational behavior framework and institutional 
“intelligence”.   
 
From a very practical and focused perspective, it will be the role of researchers to evaluate and judge the success of 
compliance through risk modeling in the pharmaceutical industry. The resulting data will show the strengths and 
weaknesses of the initial FDA approach.   
 
A broader question about risk management is whether other industrial sectors have enough similar attributes to the 
pharmaceutical industry to make risk management an important research tool.  While the initial answer may be no, 
increasingly more industrial sectors are facing similar constraints, such as more stringent government oversight and 
risk adverse consumers, and may find it advantageous to incorporate risk management in their planning 
methodologies.  For instance sectors as diverse as financial services, the defense industries and automotive 
industries may well become candidates for risk management techniques and process management repositories in the 
near future.  Yet other industries may simply improve their best practices by more formally incorporating the 
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